Literature DB >> 16157527

18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome.

Amy Tran1, Betty S Pio, Bahareh Khatibi, Johannes Czernin, Michael E Phelps, Daniel H S Silverman.   

Abstract

UNLABELLED: Extraaxillary metastases (i.e., in the absence of axillary involvement) are more likely to develop in patients with inner-quadrant (IQ) breast cancer than in patients with outer-quadrant (OQ) primary tumors. The relative difficulty of identifying extraaxillary metastases may lead to understaging of cancer in these patients. This study examined whether (18)F-FDG PET findings were differentially associated with the location of primary tumors, and with long-term prognosis, in IQ and OQ patients.
METHODS: Follow-up data were obtained for 141 patients whose breast cancer was staged by PET and who were documented to have IQ (n = 42) or OQ (n = 99) primaries. Results were stratified according to PET findings consistent with different metastatic patterns. Data were further analyzed with respect to disease outcome after a mean 3-y follow-up period.
RESULTS: Among IQ patients, progressive disease was identified in 26.1%, compared with 13.1% of OQ patients, for a relative risk (RR) of 2.0. Of patients with PET findings of isolated extraaxillary metastases, 36.1% had progressive disease, compared with 10.7% of other patients (RR = 3.4), and 61.9% of IQ patients had isolated extraaxillary metastases identified on PET, compared with 10.1% of OQ patients (RR = 6.1).
CONCLUSION: IQ patients demonstrated a 6-fold greater frequency of PET findings of isolated extraaxillary metastasis, and such findings were associated with triple the risk for disease progression. Patients with IQ tumors could be vulnerable to understaging with conventional staging approaches and may particularly benefit from PET during the staging process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157527

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  Current and future use of positron emission tomography (PET) in breast cancer.

Authors:  David A Mankoff; William B Eubank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

2.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Authors:  S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

3.  Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.

Authors:  William B Eubank; Jean H Lee; David A Mankoff
Journal:  PET Clin       Date:  2009-07-01

4.  The effect of adjuvant radiotherapy on mortality differs according to primary tumor location in women with node-positive breast cancer.

Authors:  Vincent Vinh-Hung; Pauline T Truong; Wolfgang Janni; Nam Phong Nguyen; Georges Vlastos; Gábor Cserni; Melanie E Royce; Wendy A Woodward; Donald Promish; Patricia Tai; Guy Soete; Sabine Balmer-Majno; Bruno Cutuli; Guy Storme; Christine Bouchardy
Journal:  Strahlenther Onkol       Date:  2009-03-28       Impact factor: 3.621

5.  Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo.

Authors:  Christian D Young; Andrew S Lewis; Michael C Rudolph; Marisa D Ruehle; Matthew R Jackman; Ui J Yun; Olesya Ilkun; Renata Pereira; E Dale Abel; Steven M Anderson
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

Review 6.  Sugar and fat - that's where it's at: metabolic changes in tumors.

Authors:  Christian D Young; Steven M Anderson
Journal:  Breast Cancer Res       Date:  2008-02-20       Impact factor: 6.466

7.  The use of 18F-FDG positron emission tomography to detect mediastinal lymph nodes in metastatic breast cancer.

Authors:  Cem Onal; Alper Findikcioglu; Ozan Cem Guler; Mehmet Reyhan
Journal:  Breast       Date:  2020-10-26       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.